Kobe, Japan

Kazuo Mori


Average Co-Inventor Count = 6.6

ph-index = 4

Forward Citations = 47(Granted Patents)


Location History:

  • Kobe, JA (1976 - 1978)
  • Kobe, JP (1978 - 1980)

Company Filing History:


Years Active: 1976-1980

Loading Chart...
12 patents (USPTO):Explore Patents

Title: Kazuo Mori: Innovator in Pharmaceutical Chemistry

Introduction

Kazuo Mori is a distinguished inventor based in Kobe, Japan. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic applications. With a total of 12 patents to his name, Mori's work has had a profound impact on the industry.

Latest Patents

Mori's latest patents include innovative compounds such as 1-Polyhaloalkyl-2(1H)-quinazolinone derivatives. These compounds exhibit excellent anti-inflammatory and analgesic activities with very low toxicity. They can be synthesized by reacting a trihalogenoacetamidobenzophenone derivative with ammonia. Another notable patent involves 3,4-Dihydro-2(1H)-quinazolinone derivatives, which possess pharmacological properties such as central nervous system depressant, anti-inflammatory, analgesic, and anti-microbial activities. These compounds can be produced through various chemical reactions, showcasing Mori's expertise in synthetic chemistry.

Career Highlights

Kazuo Mori is currently associated with Sumitomo Chemical Company, Limited, where he continues to innovate and develop new pharmaceutical products. His work has not only advanced scientific knowledge but has also contributed to the creation of effective medications that improve patient outcomes.

Collaborations

Mori has collaborated with notable colleagues in his field, including Shigeho Inaba and Kikuo Ishizumi. These partnerships have fostered a collaborative environment that enhances research and development efforts.

Conclusion

Kazuo Mori's contributions to pharmaceutical chemistry through his innovative patents and collaborations highlight his role as a leading inventor in the industry. His work continues to influence the development of new therapeutic agents that benefit society.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…